Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2018-04-03 16:09:53
Reporting Period:
Accepted Time:
2018-04-03 16:09:53
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1488613 Foundation Medicine Inc. FMI Services-Medical Laboratories (8071) 271316416
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1710939 J Michael Doherty C/o Foundation Medicine, Inc.
150 Second Street
Cambridge MA 02141
Head Of Product Development No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-04-01 8,621 $78.75 92,154 No 4 A Direct
Common Stock Disposition 2018-04-02 8,190 $74.87 83,964 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
  1. Represents restricted stock units issued pursuant to a Restricted Stock Unit Award Agreement and the Issuer's 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in equal quarterly installments over a three-year period with the first installment vesting on July 1, 2018.
  2. Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on April 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person.
  3. The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.60 to $75.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
  4. The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2017 in Table I of the Form 3 filed on July 5, 2017. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale.